Drug Profile
Research programme: neurodegenerative disorders therapeutics - KineMed/Bristol-Myers Squibb
Latest Information Update: 12 Nov 2013
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; KineMed
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 07 Nov 2013 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 07 Nov 2013 No development reported - Preclinical for Neurodegenerative disorders in USA (unspecified route)